TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug

Anti-Cancer Drugs

Volumn 25, Issue 8, 2014, Pages 908-916

  Gheidari, Fatemeh ^a,b   Bakhshandeh, Behnaz ^a   Teimoori Toolabi, Ladan ^b   Mehrtash, Amirhosein ^b   Ghadir, Mahdis ^b   Zeinali, Sirous ^b  

^a UNIVERSITY OF TEHRAN   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

gene silencing; human; neoplasia; oxaliplatin; RNA; small interfering; TCF4 protein

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; TCF4 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; PLATINUM COMPLEX; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN MOTIF; SENSITIZATION; SW 1396 CELL LINE; SW SC CELL LINE; SW1874 CELL LINE; SW480 CELL LINE; APOPTOSIS; CELL CYCLE; COLON TUMOR; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84905489532     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000118     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-2917.
2. Kohne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009; 14:478-488.
3. Stein U, Fleuter C, Siegel F, Smith J, Kopacek A, Scudiero DA, et al. Impact of mutant beta-catenin on ABCB1 expression and therapy response in colon cancer cells. Br J Cancer 2012; 106:1395-1405.
4. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-3008.
5. Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011; 12:570-594.
6. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000; 60:4761-4766.
7. Martins FC, Botelho MF, Cabrita AM, Torgal MI, CFD Oliveira. Cancer and deregulation of stem cells pathways. Oncol Rev 2008; 2:4.
8. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998; 8:573-581.
9. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16:3797-3804.
10. Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 2009; 10:276-286.
11. Kidani Y, Inagaki K, Iigo M, Hoshi A, Kuretani K. Antitumor activity of 1,2-diaminocyclohexane - platinum complexes against sarcoma-180 ascites form. J Med Chem 1978; 21:1315-1318.
12. Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat 2011; 14:280-296.
13. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002; 59:1914-1927.
14. Teimoori-Toolabi L, Azadmanesh K, Zeinali S. Selective suicide gene therapy of colon cancer cell lines exploiting fibroblast growth factor 18 promoter. Cancer Biother Radiopharm 2010; 25:105-116.
15. Harper SQ, Davidson BL. Plasmid-based RNA interference: construction of small-hairpin RNA expression vectors. Methods Mol Biol 2005; 309: 219-235.
16. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002; 99:14849-14854.
17. Lin SL, Chuong CM, Ying SY. A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells. Biochem Biophys Res Commun 2001; 281:639-644.
18. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003; 545 (2-3):144-150.
19. Kosciolek BA, Kalantidis K, Tabler M, Rowley PT. Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2003; 2:209-216.
20. He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005; 24:3054-3058.
21. Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, et al. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res 2010; 70:7253-7263.
22. Huang WS, Wang JP, Wang T, Fang JY, Lan P, Ma JP. ShRNA-mediated gene silencing of beta-catenin inhibits growth of human colon cancer cells. World J Gastroenterol 2007; 13:6581-6587.
23. Lazaris AC, Kavantzas NG, Zorzos HS, Tsavaris NV, Davaris PS. Markers of drug resistance in relapsing colon cancer. J Cancer Res Clin Oncol 2002; 128:114-118.
24. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
25. Van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111:241-250.
26. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005; 23:1826-1838.
27. Alison MR, Murphy G, Leedham S. Stem cells and cancer: a deadly mix. Cell Tissue Res 2008; 331:109-124.
28. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant sidepopulation colon cancer cells. Anticancer Res 2010; 30:2041-2048.
29. Andre T, Afchain P, Barrier A, Blanchard P, Larsen AK, Tournigand C, et al. Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res 2007; 1:90-97.
30. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-1071.
31. Kendziorra E, Ahlborn K, Spitzner M, Rave-Frank M, Emons G, Gaedcke J, et al. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 2011; 32: 1824-1831.
32. Trosko JE, Chang CC. Stem cell theory of carcinogenesis. Toxicol Lett 1989; 49 (2-3):283-295.
33. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434:843-850.
34. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet 2006; 7:45-54.
35. Kriegl L, Horst D, Reiche JA, Engel J, Kirchner T, Jung A. LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med 2010; 8:123.